ArticleAdvanced healthcare materials2026
Negatively Charged Peptides-Assisted Self-Assembled Mitochondria-Targeting Nanoprobe for Detecting Enterokinase and Image-Guided Navigation in Human Breast Cancer.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Surgical resection remains the primary treatment in human breast cancer. However, the accurate and rapid delineation of tumor margins intraoperatively is still a significant challenge. Herein, we designed a near-infrared fluorescent probe DCIP-ENTK by incorporating dicyanoisophorone dye with a negatively charged peptide, which can be specifically cleaved by enterokinase (ENTK, a tumor biomarker for breast cancer). In vitro experiments confirmed that the probe could quickly (<10 min), specifically, and sensitively (LOD = 0.031 U/mL) respond to ENTK. Notably, this probe was engineered as a peptide-based architecture that can self-assemble into a nanoprobe. This design not only provides excellent biocompatibility and in vivo stability, but also enables specific mitochondria-targeting within cancer cells. Upon cleavage by ENTK, the released hydrophobic fluorophores aggregated at the enzyme-rich site. This unique aggregation-induced retention effect enabled long-term, high-contrast in situ imaging of tumor margins in tumor-bearing mice and human breast cancer samples, which offers a powerful and clinically translatable tool for improving the precision of cancer surgery. Finally, we also achieved the quantitation of ENTK levels in artificial human duodenal juice with recovery rates from 93.5% to 99.8%. These results confirm the suitability of our probe for the quantitation of ENTK in real samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.